NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR USE IN DOWN SYNDROME AND ALZHEIMER`S DISEASE THERAPY
The present invention relates to nucleoside reverse transcriptase inhibitors (NRTI) or their pharmaceutically acceptable salts for use in (a) the treatment of Down syndrome or the consequences thereof or (b) the prevention, inhibition of progression or treatment of Alzheimer`s disease or the consequ...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
15.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to nucleoside reverse transcriptase inhibitors (NRTI) or their pharmaceutically acceptable salts for use in (a) the treatment of Down syndrome or the consequences thereof or (b) the prevention, inhibition of progression or treatment of Alzheimer`s disease or the consequences thereof. Pharmaceutical compositions comprising such NRTI and combinations of NRTI are provided. Kits including NRTI, combinations of NRTI, and pharmaceutical compositions comprising such NRTI and combinations of NRTI are also described.
La présente invention concerne des inhibiteurs nucléosidiques de la transcriptase inverse (NRTI) ou leurs sels pharmaceutiquement acceptables pour une utilisation dans (a) le traitement du syndrome de Down ou des conséquences de celui-ci ou (b) la prévention, l'inhibition de la progression ou le traitement de la maladie d'Alzheimer ou des conséquences de celle-ci. L'Invention concerne également des compositions pharmaceutiques comprenant de tels NRTI et des combinaisons de NRTI. L'Invention concerne également des kits comprenant NRTI, des combinaisons de NRTI, ainsi que des compositions pharmaceutiques comprenant de tels NRTI et des combinaisons de NRTI. |
---|---|
Bibliography: | Application Number: WO2022IB00673 |